This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems? (ECTAug)

This study has been withdrawn prior to enrollment.
(PI deceased; study did not start.)
Sponsor:
Information provided by (Responsible Party):
Jerrry L Lewis, University of Iowa
ClinicalTrials.gov Identifier:
NCT00988663
First received: October 1, 2009
Last updated: March 21, 2017
Last verified: March 2017
October 1, 2009
March 21, 2017
November 2009
November 2009   (Final data collection date for primary outcome measure)
Assessment of whether Memantine protects memory and cognitive impairment caused by ECT. [ Time Frame: 6 to 8 weeks ]
Same as current
Complete list of historical versions of study NCT00988663 on ClinicalTrials.gov Archive Site
Whether memantine will improve response of Depression to Electroconvulsive therapy. [ Time Frame: 6-8 weeks ]
Same as current
Not Provided
Not Provided
 
The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems?
Memantine Augmentation of Electroconvulsive Therapy in Patients With Major Depression
The purpose of this study is to determine whether memantine will enhance the therapeutic of effect on depression and prevent memory and other cognitive problems caused by ECT.
Patients will be assigned randomly either to a treatment group or a placebo groups. All patients in both groups will be receiving standard ECT. The treatment group will receive memantine. All patients will be given a battery of cognitive tests and test of depression before ECT treatments start, after the 6th ECT treatment and after the completions of ECT. An analysis will be performed to see if memantine causes any impact on the response to ECT and prevents memory and cognitive impairment.
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Major Depressive Disorder
  • Drug: memantine
    patient will receive 5mg daily for 7day then 10 mgm daily
    Other Name: Namenda
  • Drug: Placebo
    will give placebo that looks like memantine
  • Active Comparator: Memantine arm
    Patient receiving ECT and Memantine
    Intervention: Drug: memantine
  • Placebo Comparator: placebo
    25 patients receiving ECT will will receive placebo
    Interventions:
    • Drug: memantine
    • Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
November 2009
November 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Meets criteria for Major Depressive disorder

Exclusion Criteria:

  • Neurological disease
  • Mental retardation
  • Seizure disorder
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00988663
Memantine ECT trial
Yes
Not Provided
Not Provided
Jerrry L Lewis, University of Iowa
Jerrry L Lewis
Not Provided
Principal Investigator: Jerry L Lewis, MD University of Iowa Hospitals and Clinic
University of Iowa
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP